Rogier W. Sanders

This study shows that sequential vaccination can mature VRC01-class B cells into antibodies that neutralize a broad range of HIV-1 viruses.

This paper develops a consensus HCV E1E2 antigen that engages germline B cell precursors of broadly neutralizing antibodies.

This study shows that SMNP, a TLR4-targeted adjuvant, induces stronger immune activation and reduces HIV-1 reservoir size in PWH ex vivo compared to MPLA.

The paper evaluates adjuvant effects on immune responses in virosome-based SARS-CoV-2 vaccines, finding distinct impacts on humoral and cellular immunity.

This study uses cryoEM and machine learning to predict and redirect immunodominant epitopes in HIV Env, showing improved vaccine antigen design.

This study shows that STT3A is more critical than STT3B for HIV-1 Env glycosylation, affecting virus production and antibody sensitivity.

The paper identifies shared maturation pathways of V3-glycan broadly neutralizing antibody lineages in humans and rhesus macaques, revealing convergent mutations and evolution patterns.

This study defines the dynamic activation-memory cycle of human IgG memory B cells through single-cell profiling, revealing distinct reactivation trajectories and functional roles in humoral immunity.

This study shows that fusing C3d to HIV-1 Env immunogens enhances germinal center responses and improves vaccine immunogenicity.

This study compares bnAb precursor responses in infant and juvenile rhesus macaques after germline-targeting HIV Env immunization, finding higher rates in infants.

This study generates bispecific antibodies targeting two distinct HCV E1E2 epitopes, showing enhanced neutralization breadth and potency compared to monospecific antibodies.

This study stabilizes an HIV-1 clade C trimer using multiple platforms and shows improved antigenic and immunogenic properties.

The paper identifies anti-immune complex antibodies generated through repeated HIV Env immunizations and presents their structures using polyclonal epitope mapping.

This study develops bispecific antibodies that target conserved regions on the SARS-CoV-2 spike protein, showing improved neutralization breadth against multiple sarbecovirus strains.

This study shows that chemical cross-linking with EDC stabilizes HIV-1 Env trimers without significant structural distortion, improving their stability, morphology, antigenicity, and immunogenicity for vaccine development.

This paper identifies 9-O-acetylated sialic acids as a ligand for the SARS-CoV-2 NTD, revealing a dual-receptor functionality in the S1 domain that was rapidly selected against.

Designed trimers matched to viral glycoprotein termini yielded tetrahedral, octahedral and icosahedral nanoparticles with cryo-EM-verified structures that display native-like HIV Env, influenza HA and RSV F.